Calliditas Therapeutics AB
Clinical trials sponsored by Calliditas Therapeutics AB, explained in plain language.
Now part of
Asahi Kasei Corporation
3407
TOKYO
A biopharmaceutical company focused on rare diseases, particularly kidney and liver conditions.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.